Akèy › Maladi Crohn › Washington
Etid klinik pou Maladi Crohn nan Washington
22 etid pou Maladi Crohn ap chèche patisipan nan sit nan Washington.
Vil nan Washington
Tèks ofisyèl etid la (Anglè)
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
- Washington Gastroenterology - Tacoma ( Site 0295), Tacoma
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Oct 2, 2026 · NCT06651281A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Washington ( Site 5115), Seattle
- Washington Gastroenterology - Tacoma ( Site 5004), Tacoma
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Oct 2, 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Washington Gastroenterology - Bellevue /ID# 283966, Bellevue
- Washington Gastroenterology - Tacoma /ID# 284143, Tacoma
- The Vancouver Clinic /ID# 280497, Vancouver
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 2, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- GI Alliance, Bellevue
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Virginia Mason Hospital and Medical Center /ID# 265574, Seattle
- Washington Gastroenterology - Tacoma /ID# 267302, Tacoma
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06548542A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196722A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- University of Washington Medical Center, Seattle
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT06233461Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Washington Gastroenterology - Tacoma, Tacoma
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance - Bellevue-Site Number: 8400143, Bellevue
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- The Vancouver Clinic Inc. P.S.-Site Number: 8400090, Vancouver
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 23, 2026 · NCT07184944A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- Washington Gastroenterology- GIA, Tacoma
Ap rekriteFaz 4
Laj 18 a 70 · Tout sèks · Mizajou Sep 9, 2026 · NCT06045754Familial Inflammatory Bowel Disease Early Risk
- Seattle Children's Hospital, Seattle
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 0 a 55 · Tout sèks · Mizajou Aug 28, 2026 · NCT07791862A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
- GI Alliance Tacoma, Tacoma
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577843A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Seattle Children's Hospital, Seattle
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 24, 2026 · NCT05509777A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
- MultiCare Institute for Research & Innovation, Tacoma
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Aug 3, 2026 · NCT06100289A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Multicare Health System Institute for Research and Innovation, Tacoma
Ap rekriteFaz 3
Laj 2 a 17 · Tout sèks · Mizajou Jun 22, 2026 · NCT06405087Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
- Seattle Children's Hospital, Seattle
Ap rekriteFaz 4
Laj 6 a 17 · Tout sèks · Mizajou May 27, 2026 · NCT05781152A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
- Swedish Cancer Institute, Seattle
- University of Washington Medical Center - Montlake, Seattle
Ap rekriteFaz 3
Laj 18 a 65 · Tout sèks · Mizajou May 27, 2026 · NCT06227910Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- University of Washington, Seattle
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Apr 27, 2026 · NCT06456593Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)
- Seattle Children's Hospital, Seattle
Ap rekriteEtid obsèvasyon
Laj 6 a 21 · Tout sèks · Mizajou Apr 24, 2026 · NCT06315179A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Bellevue
- Mirador Therapeutics Selected Site, Silverdale
- Mirador Therapeutics Selected Site, Tacoma
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
- Seattle Children's Hospital, Seattle
Ap rekrite
Laj 8 a 21 · Tout sèks · Mizajou Jun 12, 2025 · NCT06216899Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.